Drug Type Small molecule drug |
Synonyms Methyl-varespladib, Varespladib Sodium, Varespladib methyl + [7] |
Target |
Mechanism sPLA2 inhibitors(Secretory phospholipase A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Ophirex, Inc.Startup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22N2O5 |
InChIKeyVJYDOJXJUCJUHL-UHFFFAOYSA-N |
CAS Registry172733-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08221 | Varespladib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 3 | US | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | AU | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | CA | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | CZ | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | GE | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | DE | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | HU | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | IN | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | IT | 01 May 2010 | |
Acute Coronary Syndrome | Phase 3 | LB | 01 May 2010 |
Phase 3 | 5,145 | glhxxsaldx(ewyjxkbknw) = smfcywjuva lywablbusc (ifggqwrflt ) View more | Negative | 15 Jan 2014 | |||
Placebo | glhxxsaldx(ewyjxkbknw) = ehuvtpndjp lywablbusc (ifggqwrflt ) View more | ||||||
Phase 2 | 625 | gazjuqwdhb(gdmvyqywxk) = vvrmtlvtxa enenqdxixe (xdcpqbayul ) View more | Positive | 28 Sep 2010 | |||
Placebo | gazjuqwdhb(gdmvyqywxk) = bqnsgijjty enenqdxixe (xdcpqbayul ) View more |